Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin

BACKGROUND: We compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes. METHODS: The present study was a multicenter, random...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Diabetes Metab J
Egile Nagusiak: Kim, Jong Ho, Kim, Sang Soo, Baek, Hong Sun, Lee, In Kyu, Chung, Dong Jin, Sohn, Ho Sang, Bae, Hak Yeon, Kim, Mi Kyung, Park, Jeong Hyun, Choi, Young Sik, Kim, Young Il, Hahm, Jong Ryeal, Lee, Chang Won, Jo, Sung Rae, Park, Mi Kyung, Lee, Kwang Jae, Kim, In Joo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Korean Diabetes Association 2016
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4929227/
https://ncbi.nlm.nih.gov/pubmed/27098505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4093/dmj.2016.40.3.230
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak